Platform Technologies in Drug Discovery and Validation
- 1st Edition, Volume 50 - November 18, 2017
- Latest edition
- Editor: Robert A. Goodnow
- Language: English
Platform Technologies in Drug Discovery and Validation, Volume 50, the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews… Read more
Platform Technologies in Drug Discovery and Validation, Volume 50, the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences. Topics covered in this new volume include DELT, Oligos: ASO, siRNA, CRISPR, Micro-fluidic chemistry, High throughput screening, Kinase-centric computational drug development, Virtual Screening, Phenotypic screening, PROTACS, Chemical Biology, Fragment-based lead generation, Antibody-Drug Conjugates, Antibody-recruiting small molecules, Deuteration, and Peptides.
- Unique for its treatment of platform technologies for medicinal chemistry and target validation
- Provides a single, rich volume that summaries a broad spectrum of expertise relevant to the field
- Presents state-of-the-art summaries of platform technologies
Ideally suited for chemists engaged in multidisciplinary teams for drug discovery including medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry
1. DNA-Encoded Library Technology: A Brief Guide to Its Evolution and Impact on Drug Discovery
Robert A. Goodnow Jr. and Christopher P. Davie
2. The Chemistry of Oligonucleotide Delivery
David B. Rozema
3. CRISPR–Cas9 for Drug Discovery in Oncology
Sylvie M. Guichard
4. Recent Advances of Microfluidics Technologies in the Field of Medicinal Chemistry
László Ürge, Jesus Alcazar, Lena Huck and György Dormán
5. High-Throughput Screening
Mary Jo Wildey, Anders Haunso, Matthew Tudor, Maria Webb and Jonathan H. Connick
6. Kinase-Centric Computational Drug Development
Albert J. Kooistra and Andrea Volkamer
7. Free Energy Calculation Guided Virtual Screening of Synthetically Feasible Ligand R-Group and Scaffold Modifications: An Emerging Paradigm for Lead Optimization
Robert Abel and Sathesh Bhat
8. Phenotypic Screening
Alleyn T. Plowright and Lauren Drowley
9. Targeted Protein Degradation
Nello Mainolfi and Tim Rasmusson
10. Chemical Biology in Drug Discovery
M. Paola Castaldi, Andrea Zuhl, Piero Ricchiuto and J. Adam Hendricks
11. Fragment-Based Lead Discovery
Ben J. Davis and Stephen D. Roughley
12. Antibody-Drug Conjugates
Amit Kumar, Jason White, R. James Christie, Nazzareno Dimasi and Changshou Gao
13. Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics
Patrick J. McEnaney, Christopher G. Parker and Andrew X. Zhang
14. A Decade of Deuteration in Medicinal Chemistry
Julie F. Liu, Scott L. Harbeson, Christopher L. Brummel, Roger Tung, Robert Silverman and Dario Doller
15. From Natural Peptides to Market
Claudio D. Schteingart and Jolene L. Lau
- Edition: 1
- Latest edition
- Volume: 50
- Published: November 18, 2017
- Language: English
RG
Robert A. Goodnow
Robert A. Goodnow, Jr. is currently Vice President, Chemistry Innovation at Pharmaron, Inc in Boston, MA. He completed a Ph.D. in bioorganic chemistry at Columbia University, New York, USA, followed by postdoctoral training at Princeton University, New Jersey, USA. He has worked at Roche and AstraZeneca, focusing on new lead and target discovery as well as implementing chemistry technologies in support of early drug discovery. He is the editor and author of The Handbook of DNA-Encoded Chemistry, which was published in 2014 by Wiley.
Affiliations and expertise
Pharmaron, Boston, USARead Platform Technologies in Drug Discovery and Validation on ScienceDirect